Dyadic International, Inc. (DYAI): Price and Financial Metrics


Dyadic International, Inc. (DYAI): $3.34

-0.12 (-3.47%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DYAI to Watchlist
Sign Up

Industry: Biotech


Ranked

of 502

in industry

DYAI POWR Grades


  • Growth is the dimension where DYAI ranks best; there it ranks ahead of 46.17% of US stocks.
  • DYAI's strongest trending metric is Sentiment; it's been moving up over the last 31 weeks.
  • DYAI ranks lowest in Quality; there it ranks in the 5th percentile.

DYAI Stock Summary

  • DYAI's went public 2.28 years ago, making it older than merely 4.62% of listed US stocks we're tracking.
  • The ratio of debt to operating expenses for Dyadic International Inc is higher than it is for about just 0.53% of US stocks.
  • With a price/sales ratio of 53.62, Dyadic International Inc has a higher such ratio than 94.88% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Dyadic International Inc, a group of peers worth examining would be PSNL, RAPT, PXLW, ECOR, and ACET.
  • Visit DYAI's SEC page to see the company's official filings. To visit the company's web site, go to www.dyadic.com.

DYAI Valuation Summary

  • In comparison to the median Healthcare stock, DYAI's price/sales ratio is 1463.89% higher, now standing at 56.3.
  • DYAI's price/sales ratio has moved down 16.9 over the prior 28 months.
  • Over the past 28 months, DYAI's price/earnings ratio has gone up 7.2.

Below are key valuation metrics over time for DYAI.

Stock Date P/S P/B P/E EV/EBIT
DYAI 2020-11-17 106.4 6.0 -19.7 -17.4
DYAI 2020-07-10 150.3 7.0 -28.7 -28.2
DYAI 2020-04-03 84.7 4.0 -17.1 -16.6
DYAI 2019-09-26 131.9 4.4 -30.0 -24.8
DYAI 2019-08-05 116.4 3.7 -26.5 -21.9
DYAI 2019-06-03 106.4 3.4 -24.2 -20.0

DYAI Price Target

For more insight on analysts targets of DYAI, see our DYAI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.00 Average Broker Recommendation 1.5 (Moderate Buy)

DYAI Stock Price Chart Interactive Chart >

Price chart for DYAI

DYAI Price/Volume Stats

Current price $3.34 52-week high $9.19
Prev. close $3.46 52-week low $3.15
Day low $3.33 Volume 257,800
Day high $3.45 Avg. volume 1,063,369
50-day MA $3.60 Dividend yield N/A
200-day MA $5.13 Market Cap 92.03M

Dyadic International, Inc. (DYAI) Company Bio


Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd., as well as with the Israel Institute for Biological Research; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; research collaboration with Sanofi-Aventis Deutschland GmbH; research and commercialization collaboration with Serum Institute of India Pvt.; and nonexclusive research collaboration with WuXi Biologics. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.


DYAI Latest News Stream


Event/Time News Detail
Loading, please wait...

DYAI Latest Social Stream


Loading social stream, please wait...

View Full DYAI Social Stream

Latest DYAI News From Around the Web

Below are the latest news stories about Dyadic International Inc that investors may wish to consider to help them evaluate DYAI as an investment opportunity.

Dyadic to Report Second Quarter 2021 Financial Results

JUPITER, FL / ACCESSWIRE / July 29, 2021 / Dyadic International, Inc.Conference Call InformationDate: Thursday, August 12, 2021Time: 5:00 p.

Yahoo | July 29, 2021

Dyadic rises after announcing licensing agreement for COVID-19 vaccine platform

luza studios/iStock via Getty Images Dyadic International (DYAI) has added ~18.6% in the pre-market after the company announced an agreement with Rubic Consortium for COVID-19 vaccine technology transfer and licensing. Rubic is a South African company aiming to supply cost-effective vaccines mainly for African markets. Per the terms of the agreement, Rubic will...

Seeking Alpha | July 27, 2021

Dyadic Stock Shoots Higher On Technology Transfer, Licensing Pact For COVID-19 Vaccine In African Continent

Dyadic International Inc (NASDAQ: DYAI) stock is trading higher during the morning session on high volume after signing a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium. The South African-based company is focused on discovering, developing, evaluating, and manufacturing high-quality, cost-effective vaccines for distribution primarily to African markets. Dyadic will out-license the C1 Platform for COVID-19 vaccine(s). Rubic will be responsible for designing

Yahoo | July 27, 2021

Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent

Potential for Affordable COVID-19 Immunization Coverage in Underserved African CountriesArrangement includes C1 COVID-19 vaccine technology transfer and licensing agreementProvides potential funding pathway for a C1 manufactured COVID-19 vaccine to progress through Phase II and Phase III clinical trialsEstablishes co-development basis for researching, developing and manufacturing multiple other C1 produced vaccines in addition to DYAI-100Intends to reduce African dependence on foreign vaccine su

Yahoo | July 27, 2021

Companies Like Dyadic International (NASDAQ:DYAI) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | July 22, 2021

Read More 'DYAI' Stories Here

DYAI Price Returns

1-mo N/A
3-mo -19.52%
6-mo -44.79%
1-year -62.89%
3-year 127.21%
5-year 110.06%
YTD -37.92%
2020 3.86%
2019 174.07%
2018 35.97%
2017 -16.27%
2016 -8.29%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8951 seconds.